29 
National Institutes of Health, and by Dr. Gilbert Omenn, Deputy Di 
rector, Office of Science and Technology Policy. Both witnesses rec 
ommended passage of the legislation. 
A portion of Dr. F redrickson ; s testimony follows : 
I am pleased to appear before this subcommittee today to 
testify on behalf of the Department on the Recombinant 
DXA Act (H.R. 11192 ) as reported by the Committee on 
Interstate and Foreign Commerce. 
The Department favors enactment of H.R. 11192 because 
this measure offers the most promising solution available for 
establishing national standards for the use of recombinant 
DXA techniques. 
Congressman Harley Staggers. Chairman of the Interstate 
and Foreign Commerce Committee, and Congressman Paul 
Rogers, Chairman of the Subcommittee on Health and the 
Environment, are to be commended for working effectively to 
develop an interim, two-year bill that provides for sensible 
regulation and public oversight. Your Subcommittee, Mr. 
Thornton, has also done an outstanding public service in the 
care and deliberation provided this most important research 
area in your extensive hearings over the past two years. 
H.R. 11192 reflects new scientific information and admin- 
istrative developments since the release of the XIH Guide- 
lines in June 1976 as do the revisions to the Guidelines pro- 
posed to me in September 1977 by the Recombinant DXA 
Molecule Program Advisory Committee (RAC). 
[Appendix B — 217] 
